-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We keep our 12-month price target at $210, based on 16.4x our 2026 EPS estimate, above IQV's one-year historical forward average of 15.6x but a discount to its five-year historical forward average of 20.6x. This is justified by recent headwinds for key life sciences end markets due to macroeconomic pressures, uncertain tariff and research funding policy, and weaker biotech spending and clinical trial activity, in our view. We raise our 2026 EPS estimate to $12.80 from $12.70 and lower our 2027 estimate by $0.07 to $14.12. Adjusted for IQV's new segment reporting, R&DS saw net new bookings of $2.5B in Q1 2026 (up 3.6% Y/Y), generating a book-to-bill ratio of 1.04x, somewhat weaker than recent trends. Management attributed this to an unfavorable clinical trial mix rather than an indicator of weakening demand. Per Q1 earnings commentary, the company has deployed 192 AI agents across 64 use cases, with 19 of the top-20 pharmaceutical companies having adopted some of these offerings.